 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- VMT
[212Pb]Pb-VMT-?-NET dosimetry in patients with advanced SSTR2-positive tumors in the VMT-?-NET-T101 trial (Science Pavilion) - May 10, 2025 - Abstract #SNMMI2025SNMMI_1455;
P1/2
Dosimetric analysis of VMT-?-NET-T101 multi-timepoint imaging with [203Pb]Pb-VMT-?-NET in the screening stage of the trial demonstrates that [212Pb]Pb-VMT-?-NET has a favorable ratio of absorbed dose in tumors relative to kidneys. Additional comprehensive dosimetry analyses for sub-study patients will be presented at the congress.
- VMT, Lutathera (lutetium Lu 177 dotatate) / Novartis
177Lu-DOTATATE (LUMOD) and 212Pb-VMT-alpha-NET Trials at University of Iowa () - May 10, 2025 - Abstract #SNMMI2025SNMMI_399;
Additional comprehensive dosimetry analyses for sub-study patients will be presented at the congress. Sponsored by Dosimetry Task Force
- VMT
[212Pb]VMT-?-NET therapy in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs): Dose-limiting toxicity (DLT) observation participants after 1 year follow-up and preliminary report for expansion participants. (Hall D1) - Apr 23, 2025 - Abstract #ASCO2025ASCO_3543;
P1/2
Sponsored by Dosimetry Task Force Clinical Trial Registration Number: NCT05636618 The abstract will be released to the public on May 22, 2025 at 4:00 PM CDT
- || VMT
Review, Journal: Nuclear medicine and perspective thoughts in the diagnosis and treatment of pheochromocytoma and paraganglioma. (Pubmed Central) - Mar 5, 2025
It also provides insight into the use of proliferating cell nuclear antigen (PCNA) inhibitors in combination with therapeutics in aggressive/metastatic PPGL. Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL.
- | VMT-?-NET / Perspective Therap
Enrollment open: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - Feb 21, 2025
P1/2, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Through a comprehensive review of the latest developments and clinical practice, this review aims to guide healthcare professionals in improving the diagnostic accuracy and therapeutic efficacy of PPGL. Suspended --> Recruiting
- | VMT-?-NET / Perspective Therap
Trial suspension: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - Feb 12, 2025
P1/2, N=66, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | VMT-?-NET / Perspective Therap
Enrollment open: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - Feb 4, 2025
P1/2, N=66, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Not yet recruiting --> Recruiting
- VMT
Interim safety and efficacy data of [212Pb]VMT-?-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs). (Level 1, West Hall; Poster Bd #: F11) - Dec 17, 2024 - Abstract #ASCOGI2025ASCO_GI_555;
P1/2
Clinical Trial Registration Number: NCT05636618. The abstract will be released to the public on January 21, 2025 at 10:00 PM UTC
- | VMT
Journal: Lead-it-EAZY! GMP-compliant production of [212Pb]Pb-PSC-PEG2-TOC. (Pubmed Central) - Nov 28, 2024
The Lead-it-EAZY process performed stable and robust over ten radiosyntheses and yielded sterile [212Pb]Pb-VMT-?-NET in high purity for patient application. By changing the precursor this process could easily be adapted to other 212Pb-radiopharmaceuticals.
- VMT
Preliminary safety and efficacy data of [212Pb] VMT-a-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs) () - Nov 1, 2024 - Abstract #NANETS2024NANETS_119;
- VMT
Image guided evaluation of 212Pb-VMT-?-NET in metastatic Neuroendocrine tumors: Bio distribution and Dosimetry (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2421;
The SPECT/CT imaging with 212Pb-VMT-?-NET showed prompt tumor accumulation, high tumor retention, and rapid renal excretion. Image guided dosimetry of 212Pb-peptide for targeted alpha therapy seems to be an accurate and a straight forward option for dose calculation, however, the dosimetry estimate for clinical translation requires a larger study.
- VMT
Interim results of 212Pb-VMT-?-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First In-human Clinical Results on Safety and Efficacy (Hall Y1-Y3) - Sep 27, 2024 - Abstract #EANM2024EANM_748;
Also, the treatment appears to be safe, with minimal and transient side effects. However, the long-term survival data will emerge with extended follow-up.
- VMT
Impact of molar activity on [203Pb]Pb-VMT-?-NET biodistribution profile in mice bearing neuroendocrine tumor xenograft (Hall X1-X4) - Sep 27, 2024 - Abstract #EANM2024EANM_483;
Results suggest that a "sweet spot" of total injected mass of [203Pb]VMT-?-NET (<0.5 nmol) can be found in which tumor to normal ratio can be optimized. These findings provide a potential new strategy that could be used to optimize this aspect of RPT.
- ||| VMT-?-NET / Perspective Therap
Enrollment change, Trial completion date, Trial primary completion date: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - Aug 23, 2024
P1/2, N=280, Recruiting, Sponsor: Perspective Therapeutics
These findings provide a potential new strategy that could be used to optimize this aspect of RPT. N=52 --> 280 | Trial completion date: Jan 2028 --> Dec 2029 | Trial primary completion date: Sep 2026 --> Nov 2029
- | VMT
Journal: Lead-203 VMT-?-Neuroendocrine Tumor Scintigraphy: A Promising Theranostics Agent. (Pubmed Central) - Jul 11, 2024
As Pb-203 presents an accurate diagnostic surrogate to Pb-212, imaging with Pb-203-labelled peptides can be an important prerequisite to assess the feasibility of TAT with Pb-212-labelled agents. Here, we present the imaging data of a patient with metastatic NET with Pb-203 VMT-?-NET, a somatostatin receptor targeting agent, and demonstrate the matching distribution of Pb-203 VMT-?-NET with Ga-68 DOTANOC.
- | VMT-?-NET / Perspective Therap
New P1 trial: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers (clinicaltrials.gov) - Jun 28, 2024
P1, N=120, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | VMT-?-NET / Perspective Therap
New P1/2 trial: Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy (clinicaltrials.gov) - May 24, 2024
P1/2, N=53, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- 212Pb-VMT
212Pb-VMT-α-NET α-PRRT planning based on 203Pb-VMT-α-NET predictive dosimetry (717AB (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1785;
P1
To our knowledge, this work is the first report of using 203Pb-based predictive dosimetry for personalized therapy with any 212Pb-based radiopharmaceutical in humans. We report initial dosimetry results for 203/212Pb-VMT-?-NET, and initial treatments based upon personalized dosimetry.
- 212Pb-VMT
212Pb-VMT-α-NET Targeted Alpha Therapy in Metastatic Neuroendocrine Tumors: First in Human study on Safety and Efficacy (717AB (Convention Center); In-Person) - May 8, 2024 - Abstract #SNMMI2024SNMMI_1757;
8 out of the 12 patients showed a marked reduction in functional tumour volume with a significant improvement in symptoms even at this rather low dose of Pb212 VMT -?-NET therapy. None of the patients demonstrated a clinically significant grade 3 adverse event.
- || VMT-?-NET / Perspective Therap
Enrollment closed: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov) - Apr 26, 2024
P1, N=24, Active, not recruiting, Sponsor: David Bushnell
None of the patients demonstrated a clinically significant grade 3 adverse event. Recruiting --> Active, not recruiting
- || VMT-?-NET / Perspective Therap
Enrollment open, Trial primary completion date: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - Apr 25, 2024
P1, N=20, Enrolling by invitation, Sponsor: Yusuf Menda
Recruiting --> Active, not recruiting Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2023 --> Sep 2025
- || VMT-?-NET / Perspective Therap
New P1 trial: A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov) - Nov 28, 2023
P1, N=24, Recruiting, Sponsor: David Bushnell
- || VMT-?-NET / Perspective Therap
Enrollment closed: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - Nov 18, 2023
P1, N=20, Active, not recruiting, Sponsor: Yusuf Menda
Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2023 --> Sep 2025 Enrolling by invitation --> Active, not recruiting
- ||| VMT-?-NET / Perspective Therap
Enrollment open: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - Nov 8, 2023
P1/2, N=52, Recruiting, Sponsor: Viewpoint Molecular Targeting
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- || VMT-?-NET / Perspective Therap
Trial initiation date: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - May 9, 2023
P1/2, N=52, Not yet recruiting, Sponsor: Viewpoint Molecular Targeting
Not yet recruiting --> Recruiting Initiation date: Mar 2023 --> Jul 2023
- | VMT-?-NET / Perspective Therap
Trial primary completion date: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - Apr 18, 2023
P1, N=20, Enrolling by invitation, Sponsor: Yusuf Menda
Initiation date: Mar 2023 --> Jul 2023 Trial primary completion date: Jun 2023 --> Dec 2023
- |||| VMT-?-NET / Perspective Therap
New P1/2 trial: 212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov) - Dec 5, 2022
P1/2, N=52, Not yet recruiting, Sponsor: Viewpoint Molecular Targeting
- || VMT-?-NET / Perspective Therap
Enrollment open: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - Sep 19, 2022
P1, N=20, Enrolling by invitation, Sponsor: Yusuf Menda
Trial primary completion date: Jun 2023 --> Dec 2023 Not yet recruiting --> Enrolling by invitation
- || VMT-?-NET / Perspective Therap
Trial initiation date: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - May 4, 2022
P1, N=20, Not yet recruiting, Sponsor: Yusuf Menda
Not yet recruiting --> Enrolling by invitation Initiation date: Feb 2022 --> Jul 2022
- || VMT-?-NET / Perspective Therap
New P1 trial: A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent (clinicaltrials.gov) - Nov 7, 2021
P1, N=20, Not yet recruiting, Sponsor: Yusuf Menda